EQUITIES

Robust. Fundamental. Dynamic.

Our teams exercise independent thought with high conviction, resulting in portfolios that we believe are well positioned to address our clients' challenges – all within robust risk control frameworks.

vd-icon_Currency_CashUSD

$229.4bn
Equities Assets Under Management

vd-icon_People_3_Group v3

152
Equities Investment
Professionals

vd-icon_Bulleye_Target v3

20
Average Years’ Financial
Industry Experience

As at 31 December 2024

<span class="notranslate">no data</span>

$229.4bn
Equities Assets Under Management

152
Equities Investment
Professionals

20
Average Years’ Financial
Industry Experience

As at 31 December 2024

We measure success by a single factor: client outcomes. As a pure asset manager, our sole mission is to deliver consistent long-term risk-adjusted returns that exceed our benchmarks and peers, regardless of the prevailing investment landscape.

Featured strategies

Global Life Sciences

By understanding the science and business of health care, our experienced team seeks to invest in companies addressing unmet medical needs or improving efficiencies.

Biotechnology Innovation

A biotechnology strategy that seeks to leverage a disciplined approach to identify compelling opportunities across the biotech landscape in both public and private investments

Global Technology Leaders

A global approach to investing in technology companies from a highly experienced team



Insights

Are the tides rising for European equities in 2025?

European Equities Portfolio Manager Robert Schramm-Fuchs explores the events shaping the future of European markets.

Widening the lens: Revisiting the case for non-U.S. stocks

After more than a decade of outperformance, U.S. stocks have come to dominate many equity portfolios.

Japanese equities: “Behind where people go, a way for a mountain of flowers”

Unlike cherry blossoms, the attractiveness of Japanese stocks is anything but fleeting.